PDCD1 and neoplasm: With respect to the survival results, at Day 35 after the primary tumor implantation, anti-CD8 neutralizing antibody treatment reduced the abundance of tumor-infiltrating CD8+ T cells, which were observed to be elevated in mice treated with CBDCA and anti-PD-1 antibodies (Figures 5D–F).